GlassScriptPhysician profile
Michael W Milbourne
NPI 1255399366
$8,619.16
in general payments reported to CMS, 2019-2025
32 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $737 · 2021: $1,122 · 2022: $1,520 · 2023: $1,328 · 2024: $1,862 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,334 · Education: $43.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,334.11 |
| Education | $43.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,681.45 | 2019-2025 | |
| Lilly USA, LLC | $1,151.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $913.84 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $867.24 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $821.81 | 2019-2025 | Jardiance |
| Amgen INC. | $790.49 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $666.86 | 2019-2025 | |
| Corcept Therapeutics | $333.39 | 2023-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $163.09 | 2019-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $155.23 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.08 | 2022 | |
| Boston Scientific Corporation | $118.52 | 2020-2024 | Bodyguardian |
| Exact Sciences Corporation | $105.93 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $101.89 | 2019-2021 | |
| Scpharmaceuticals INC. | $92.92 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agepha Pharma Fz LLC | $80.92 | 2024-2025 | Lodoco |
| Fidia Pharma USA INC. | $75.98 | 2022-2025 | Hymovis, Triluron |
| Apria Healthcare LLC | $54.61 | 2021 | |
| Abbott Laboratories | $44.93 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $40.45 | 2020-2021 | |
| Edwards Lifesciences Corporation | $36.68 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Akcea Therapeutics, INC. | $27.56 | 2019 | |
| Infobionic, INC | $19.17 | 2020 | |
| Dexcom, INC. | $18.11 | 2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $17.68 | 2023 | |
| Esperion Therapeutics, INC. | $16.51 | 2021 | |
| Bioventus LLC | $16.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2025 | Eliquis |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Orthogenrx INC. | $14.41 | 2019 | |
| Abbvie INC. | $14.40 | 2019 | |
| Allergan, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Milbourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.